Ownership and insider activity for Quoin Pharmaceuticals, Ltd. (QNRX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment.
Price
| Price | $6.90 |
| Market Cap | $14M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-31 | Carter Denise P. | P-Purchase | 20,490 | $100K |
| 2026-08-31 | Carter Denise P. | P-Purchase | 10,245 | $62K |
| 2026-08-31 | Myers Michael | P-Purchase | 20,490 | $100K |
| 2026-08-31 | Myers Michael | P-Purchase | 10,245 | $62K |
| 2026-08-31 | Lawlor Sally Bridget | P-Purchase | 10,244 | $50K |
| 2026-08-31 | Lawlor Sally Bridget | P-Purchase | 5,122 | $31K |
| 2026-08-31 | Culverwell Anthony James | P-Purchase | 6,146 | $30K |
| 2026-08-31 | Culverwell Anthony James | P-Purchase | 3,073 | $19K |
| 2026-08-27 | LANGER DENNIS | A-Award | 34,534 | $178K |
| 2026-08-27 | Culverwell Anthony James | A-Award | 31,352 | $161K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.6M | $4.0M | $4.8M | $5.2M | $323832 | $7.5M | $2.9M | $2.4M | $3.6M | $3.82B |
| Short-term Investments | $6.4M | $4.0M | 0 | 0 | 0 | 0 | $10.0M | $8.3M | $10.4M | $14.9M |
| Receivables | $172007 | $70572 | $57804 | $77301 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $8.4M | $8.2M | $5.0M | $5.4M | $465170 | $8.2M | $13.4M | $11.3M | $14.9M | $20.0M |
| Property, Plant & Equipment | $356746 | $387139 | $413193 | $672553 | $1.9M | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | $1.0M | $912648 | $808604 | $704561 | $583334 | $483334 | $383.3M |
| Total Assets | $8.8M | $8.7M | $5.5M | $6.2M | $1.4M | $9.4M | $14.5M | $12.2M | $15.7M | $20.4M |
| Accounts Payable | $348951 | $490549 | $237372 | $45744 | 0 | $923239 | $605600 | $526523 | $905704 | $1.3M |
| Short-term Debt | $15070 | 0 | 0 | $114649 | $1.2M | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $905507 | $1.2M | $1.3M | $1.1M | $8.0M | $4.6M | $3.5M | $3.6M | $4.2M | $5.5M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $1.4M | $3.3M | $1.8M | $1.9M | $8.0M | $8.7M | $7.1M | $6.5M | $6.5M | $7.3M |
| Retained Earnings | -$9.3M | -$18.4M | -$22.5M | -$29.2M | -$6.6M | -$28.1M | -$37.5M | -$46.2M | -$55.2M | -$71.0M |
| Total Equity | $7.4M | $5.4M | $3.7M | $4.3M | -$6.6M | $657032 | $7.4M | $5.7M | $9.2M | $13.1M |
| Total Debt | $15070 | 0 | 0 | $310654 | $1.2M | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -$8.0M | -$8.0M | -$4.8M | -$4.9M | $889481 | -$7.5M | -$12.9M | -$10.7M | -$14.1M | -$3.82B |
| Working Capital | $7.5M | $7.0M | $3.7M | $4.3M | -$7.5M | $3.6M | $9.8M | $7.7M | $10.7M | $14.5M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 1.76 |
Profitability
| Return on Equity | -304.87% |
| Return on Invested Capital | -359.18% |
| Return on Assets | -156.71% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CYCN · KTTA · NBY · PLRZ · PMCB · RADX · TCRT
Explore sector: Healthcare · Biotechnology
More sections of QNRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks